Cognitive Screening with the Italian International HIV Dementia Scale in People Living with HIV: A Cross-Sectional

Maristella Belfiori1, Francesco Salis1,2, Sergio Angioni1

  • 1Department of Medical Sciences and Public Health, University of Cagliari, 09042 Cagliari, Italy.

PubMed

Insights

The Italian International HIV Dementia Scale (IHDS-IT) shows fair accuracy in detecting cognitive impairment in HIV patients, with a new optimal cut-off score of 9 or below. This tool aids in initial screening for HIV-associated neurocognitive disorders.

Area of Science:

  • Neurology
  • Infectious Diseases
  • Psychiatry

Background:

  • HIV-associated neurocognitive disorders (HANDs) remain a challenge despite combination antiretroviral therapy (cART).
  • Neuropsychological assessments for HANDs diagnosis are resource-intensive.
  • Brief screening tools are vital for initial evaluations of cognitive impairment in HIV patients.

Purpose of the Study:

  • To assess the Italian version of the International HIV Dementia Scale (IHDS-IT).
  • To evaluate the sensitivity and specificity of IHDS-IT in detecting cognitive impairment among HIV patients.
  • To determine an optimal cut-off score for IHDS-IT in this population.

Main Methods:

  • A cross-sectional study of 294 HIV patients (≥30 years) at the University of Cagliari.
  • Cognitive function assessed using the Montreal Cognitive Assessment (MoCA) and IHDS.
  • Statistical analyses included correlation, Receiver Operating Characteristic (ROC) analysis, and Youden J statistic.

Main Results:

  • IHDS and MoCA scores showed a moderate positive correlation (rho = 0.411, p < 0.0001).
  • ROC analysis identified an IHDS-IT cut-off of ≤9 with an Area Under the Curve (AUC) of 0.76, 71.7% sensitivity, and 67.2% specificity.
  • A cut-off of ≤9 IHDS-IT correctly identified 73.1% of patients with MoCA scores < 23.

Conclusions:

  • The IHDS-IT demonstrates fair diagnostic accuracy for cognitive impairment in HIV patients.
  • A lower optimal cut-off (≤9) was identified compared to previous reports, potentially due to cohort characteristics.
  • Further longitudinal studies are needed to validate these findings and the proposed cut-off.

Related Concept Videos

Intellectual Disability01:29

Intellectual Disability

Intellectual disability (ID) is a neurodevelopmental condition characterized by deficits in intellectual and adaptive functioning that manifest during the developmental period. This condition encompasses challenges in reasoning, memory, problem-solving, and learning, accompanied by impairments in everyday life skills, such as communication, self-care, and social interactions. Intellectual disability affects approximately 1% of the population in the United States, impacting an estimated 5...
159
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
165
Negative and Cognitive Symptoms of Schizophrenia01:30

Negative and Cognitive Symptoms of Schizophrenia

Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
123
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260